SPIMACO Overview
- Year Founded
-
1986
- Status
-
Public
- Employees
-
309
- Stock Symbol
-
2070
- Investments
-
7
- Share Price
-
$6.34
- (As of Thursday Closing)
SPIMACO General Information
Description
Saudi Pharmaceutical Industries & Medical Appliances Corp is involved in the manufacturing of basic chemical substances and products; medicines for human use, including cosmetics; pharmaceutical production and wholesale and retail of medicines and related products; development and marketing of medicinal and pharmaceutical products; research and development in medical science activities; operating and maintaining the healthcare facilities and any investments in related industries. The segments of the company are Pharmaceutical Manufacturing, Trading and Distribution services, and Healthcare Services, out of which the company derives maximum revenue from the Pharmaceutical Manufacturing segment. Its geographical segments are Saudi Arabia, Egypt, the Middle East, Morocco, and Algeria.
Contact Information
Website
www.spimaco.com.saCorporate Office
- PO BOX 20001
- Riyadh 11455
- Saudi Arabia
Corporate Office
- PO BOX 20001
- Riyadh 11455
- Saudi Arabia
SPIMACO Stock Performance
As of 12-Nov-2026, SPIMACO’s stock price is $6.34. Its current market cap is $756M with 119M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.34 | $6.46 | $6.07 - $8.82 | $756M | 119M | 418K | $0.48 |
SPIMACO Financials Summary
As of 30-Jun-2026, SPIMACO has a trailing 12-month revenue of $462M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,157,361 | 1,159,050 | 1,385,976 | 1,477,596 |
| Revenue | 461,733 | 454,665 | 447,237 | 440,201 |
| EBITDA | 109,115 | 103,286 | 65,118 | 40,147 |
| Net Income | 56,964 | 49,114 | 6,524 | (13,489) |
| Total Assets | 1,128,702 | 1,163,304 | 1,148,286 | 1,014,558 |
| Total Debt | 375,453 | 382,007 | 402,105 | 292,607 |
SPIMACO Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
SPIMACO Comparisons
Industry
Financing
Details
SPIMACO Competitors (16)
One of SPIMACO’s 16 competitors is Gulf Pharmaceutical Industries, a Corporation company based in Ras Al Khaimah, United Arab Emirates.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gulf Pharmaceutical Industries | Corporation | Ras Al Khaimah, United Arab Emirates | ||||
| Sun Pharmaceutical Industries | Corporation | Mumbai, India | ||||
| Biocon | Formerly PE-Backed | Bengaluru, India | ||||
| Cipla | Corporation | Mumbai, India | ||||
| Hoechst Pakistan | Corporate Backed or Acquired | Karachi, Pakistan |
SPIMACO Signals
SPIMACO Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
SPIMACO Investments & Acquisitions (7)
SPIMACO’s most recent deal was a Merger/Acquisition with Dammam Pharma for . The deal was made on 14-Dec-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Dammam Pharma | 14-Dec-2023 | Merger/Acquisition | Drug Discovery | ||
| Osmopharm | 21-Nov-2023 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Meivo Pharmaceuticals | 08-Dec-2015 | Merger/Acquisition | Pharmaceuticals | ||
| Mepho International Industry | 29-Nov-2015 | Merger/Acquisition | Pharmaceuticals | ||
| EirGen Pharma | 24-Mar-2012 | Corporate | Pharmaceuticals |
SPIMACO ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
41.47 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
SPIMACO Exits (1)
SPIMACO’s most recent exit was on 24-Mar-2012 from EirGen Pharma. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| EirGen Pharma | 24-Mar-2012 | Completed |
|
SPIMACO Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Osmopharm | Bedano, Switzerland | 1994 |
SPIMACO FAQs
-
When was SPIMACO founded?
SPIMACO was founded in 1986.
-
Where is SPIMACO headquartered?
SPIMACO is headquartered in Riyadh, Saudi Arabia.
-
What is the size of SPIMACO?
SPIMACO has 309 total employees.
-
What industry is SPIMACO in?
SPIMACO’s primary industry is Pharmaceuticals.
-
Is SPIMACO a private or public company?
SPIMACO is a Public company.
-
What is SPIMACO’s stock symbol?
The ticker symbol for SPIMACO is 2070.
-
What is the current stock price of SPIMACO?
As of 12-Nov-2026 the stock price of SPIMACO is $6.34.
-
What is the current market cap of SPIMACO?
The current market capitalization of SPIMACO is $756M.
-
What is SPIMACO’s current revenue?
The trailing twelve month revenue for SPIMACO is $462M.
-
Who are SPIMACO’s competitors?
Gulf Pharmaceutical Industries, Sun Pharmaceutical Industries, Biocon, Cipla, and Hoechst Pakistan are some of the 16 competitors of SPIMACO.
-
What is SPIMACO’s annual earnings per share (EPS)?
SPIMACO’s EPS for 12 months was $0.48.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process